1. Home
  2. VALN vs GERN Comparison

VALN vs GERN Comparison

Compare VALN & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Valneva SE

VALN

Valneva SE

HOLD

Current Price

$10.30

Market Cap

855.8M

Sector

Health Care

ML Signal

HOLD

Logo Geron Corporation

GERN

Geron Corporation

HOLD

Current Price

$1.39

Market Cap

900.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VALN
GERN
Founded
2012
1990
Country
France
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
855.8M
900.1M
IPO Year
2021
1996

Fundamental Metrics

Financial Performance
Metric
VALN
GERN
Price
$10.30
$1.39
Analyst Decision
Strong Buy
Buy
Analyst Count
4
7
Target Price
$15.75
$3.00
AVG Volume (30 Days)
19.5K
9.1M
Earning Date
11-20-2025
02-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$211,089,992.00
$183,403,000.00
Revenue This Year
$3.64
$147.42
Revenue Next Year
$12.23
$37.07
P/E Ratio
N/A
N/A
Revenue Growth
13.48
522.13
52 Week Low
$4.56
$1.04
52 Week High
$12.25
$3.12

Technical Indicators

Market Signals
Indicator
VALN
GERN
Relative Strength Index (RSI) 54.28 54.24
Support Level $9.62 $1.26
Resistance Level $10.32 $1.37
Average True Range (ATR) 0.30 0.08
MACD 0.03 -0.00
Stochastic Oscillator 62.50 52.27

Price Performance

Historical Comparison
VALN
GERN

About VALN Valneva SE

Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.

About GERN Geron Corporation

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.

Share on Social Networks: